AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
FDA clears BristolMyers' YERVOY for treatment of metastatic melanoma.
(From Pharma)
M2PHARMA-March 28, 2011-FDA clears Bristol-Myers' YERVOY for treatment of metastatic melanoma (C)2011 M2 COMMUNICATIONS http://www.m2.com
28 March 2011 - US-based biopharmaceutical company Bristol-Myers Squibb Company (NYSE: BMY) announced on Saturday that the US Food and Drug Administration (FDA) has approved YERVOY (ipilimumab) 3 mg/kg for the treatment of patients with unresectable (inoperable) or metastatic melanoma.
YERVOY is the first and only therapy for unresectable or metastatic melanoma to demonstrate a significant improvement in overall survival based on results from a pivotal randomised, double-blind Phase III study.
The …
-
- Avax Technologies announces Special Protocol Assessment (SPA) agreement with...
-
News wire article from: Chemical Business Newsbase
October 12, 2006
700+ words
-
- Vical completes enrolment in Allovectin-7 Phase III trial for metastatic...
-
News wire article from: Chemical Business Newsbase
January 28, 2010
700+ words
-
- Antigenics announces preliminary survival data from its randomised Phase III...
-
News wire article from: Asia Africa Intelligence Wire
October 10, 2005
700+ words
-
- Eli Lilly suspends Phase III trial in metastatic melanoma.
-
News wire article from: Chemical Business Newsbase
December 13, 2010
700+ words
-
- GlaxoSmithKline announces start of two Phase III studies in...
-
News wire article from: Chemical Business Newsbase
January 24, 2011
700+ words
